Modeling the heterogeneous intestinal absorption of propiverine extended-release

被引:4
|
作者
Weiss, Michael [1 ,2 ]
Sermsappasuk, Pakawadee [2 ]
Siegmund, Werner [3 ]
机构
[1] Univ Halle Wittenberg, Dept Pharmacol, D-06097 Halle, Saale, Germany
[2] Naresuan Univ, Fac Pharmaceut Sci, Phitsanulok, Thailand
[3] Ernst Moritz Arndt Univ Greifswald, Div Clin Pharmacol, Inst Pharmacol, Greifswald, Germany
关键词
Heterogenous absorption; Propiverine; Bioavailability; Dissolution time; DRUG ABSORPTION; EXPRESSION; IMMEDIATE; TRANSIT;
D O I
10.1016/j.ejps.2015.05.010
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
Propiverine is a widely used antimuscarinic drug with bioavailability that is limited by intestinal first-pass extraction. To study the apparent heterogeneity in intestinal first-pass extraction, we performed a population analysis of oral concentration-time data measured after administration of an extended-release formulation of propiverine in ten healthy subjects. Using an inverse Gaussian function as input model, the assumption that the systemically available fraction increases as a sigmoidal function of time considerably improved the fit. The step-like increase in this fraction at time t = 3.7 h predicted by the model suggests that propiverine is predominantly absorbed in colon. A nearly perfect correlation was found between the estimates of bioavailability and mean dissolution time. (C) 2015 Elsevier B.V. All rights reserved.
引用
收藏
页码:133 / 137
页数:5
相关论文
共 50 条
  • [31] Polymers for extended-release administration
    Marion S. Paolini
    Owen S. Fenton
    Chandrabali Bhattacharya
    Jason L. Andresen
    Robert Langer
    Biomedical Microdevices, 2019, 21
  • [32] Extended-release formulations in epilepsy
    Verrotti, Alberto
    Salladini, Carmela
    Di Marco, Giovanna
    Pisciella, Floriana
    Chiarelli, Francesco
    JOURNAL OF CHILD NEUROLOGY, 2007, 22 (04) : 419 - 426
  • [33] Extended-Release Intramuscular Naltrexone
    Tracy Swainston Harrison
    Greg L. Plosker
    Susan J. Keam
    Drugs, 2006, 66 : 1741 - 1751
  • [34] MORE ON EXTENDED-RELEASE ACETAMINOPHEN
    TEMPLE, AR
    MRAZIK, TJ
    NEW ENGLAND JOURNAL OF MEDICINE, 1995, 333 (22): : 1508 - 1508
  • [35] Polymers for extended-release administration
    Paolini, Marion S.
    Fenton, Owen S.
    Bhattacharya, Chandrabali
    Andresen, Jason L.
    Langer, Robert
    BIOMEDICAL MICRODEVICES, 2019, 21 (02)
  • [36] Extended-release morphine products
    McCaffery, M
    Lochmann, C
    AMERICAN JOURNAL OF NURSING, 1996, 96 (04) : 65 - 65
  • [37] Extended-release acetaminophen overdose
    Cetaruk, EW
    Dart, RC
    Horowitz, RS
    Hurlbut, KM
    JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 1996, 275 (09): : 686 - 686
  • [38] Tramadol Extended-Release Tablets
    Philip I. Hair
    Monique P. Curran
    Susan J. Keam
    Drugs, 2006, 66 : 2017 - 2027
  • [39] A multiphasic absorption model best characterizes gastrointestinal absorption of divalproex sodium extended-release tablets
    Dutta, Sandeep
    Reed, Ronald C.
    JOURNAL OF CLINICAL PHARMACOLOGY, 2006, 46 (08): : 952 - 957
  • [40] Effects of Extended-Release Niacin and Extended-Release Niacin/Laropiprant on the Pharmacokinetics of Simvastatin in Healthy Subjects
    Lauring, Brett
    Dishy, Victor
    De Kam, Pieter-Jan
    Crumley, Tami
    Wenning, Larissa
    Liu, Fang
    Sisk, Christine
    Wagner, John
    Lai, Eseng
    AMERICAN JOURNAL OF THERAPEUTICS, 2015, 22 (05) : 367 - 376